Qube Research & Technologies (QRT)
MLTX icon

Qube Research & Technologies (QRT)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,300
Closed -$568K – 4398
2024
Q1 		$568K Buy
+11,300
New +$613K ﹤0.01% 2471

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MLTX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 42,917 shares worth $800K. The stake represents ﹤0.01% of the portfolio and ranks #2580 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in MLTX as recently as Q1 2024.

Qube Research & Technologies (QRT) first reported a position in MLTX in Q4 2023 and has held it in 3 quarters since. The position peaked at $1.14M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Qube Research & Technologies (QRT) held 42,917 shares of MoonLake Immunotherapeutics worth $800K as of Q1 2026.
  • MoonLake Immunotherapeutics was a new Qube Research & Technologies (QRT) position in Q1 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2580 holding.
  • Qube Research & Technologies (QRT) first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 3 quarters since.
  • Qube Research & Technologies (QRT)'s MoonLake Immunotherapeutics position peaked at $1.14M in Q4 2023.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.